Rapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine‐based approach in diverse healthcare systems
Open Access
- 31 December 2024
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (1) , e70105
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common global cause of chronic liver disease and remains under‐recognized within healthcare systems. Therapeutic interventions are rapidly advancing for its inflammatory phenotype, nonalcoholic steatohepatitis (NASH) at all stages of disease. Diagnosis codes alone fail to recognize and stratify at‐risk patients accurately. Our work aims to rapidly identify NAFLD patients within large electronic health record (EHR) databases for automated stratification and targeted intervention based on clinically relevant phenotypes. We present a rule‐based phenotyping algorithm for efficient identification of NAFLD patients developed using EHRs from 6.4 million patients at Columbia University Irving Medical Center (CUIMC) and validated at two independent healthcare centers. The algorithm uses the Observational Medical Outcomes Partnership (OMOP) Common Data Model and queries structured and unstructured data elements, including diagnosis codes, laboratory measurements, and radiology and pathology modalities. Our approach identified 16,006 CUIMC NAFLD patients, 10,753 (67%) previously unidentifiable by NAFLD diagnosis codes. Fibrosis scoring on patients without histology identified 943 subjects with scores indicative of advanced fibrosis (FIB‐4, APRI, NAFLD–FS). The algorithm was validated at two independent healthcare systems, University of Pennsylvania Health System (UPHS) and Vanderbilt Medical Center (VUMC), where 20,779 and 19,575 NAFLD patients were identified, respectively. Clinical chart review identified a high positive predictive value (PPV) across all healthcare systems: 91% at CUIMC, 75% at UPHS, and 85% at VUMC, and a sensitivity of 79.6%. Our rule‐based algorithm provides an accurate, automated approach for rapidly identifying, stratifying, and sub‐phenotyping NAFLD patients within a large EHR system.Keywords
All Related Versions
Funding Information
- National Center for Advancing Translational Sciences
- National Institutes of Health (UL1TR001873, UL1TR001878)
- National Institutes of Health (R35GM131905, 2R01AA026302)
- National Institute of General Medical Sciences (R01GM138597)
- National Human Genome Research Institute (R01HG010067, R01HG012670)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK132138, R01DK131547)
This publication has 26 references indexed in Scilit:
- Designing a Clinical Data Warehouse Architecture to Support Quality Improvement Initiatives.2017
- Characterizing treatment pathways at scale using the OHDSI networkProceedings of the National Academy of Sciences, 2016
- Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver DiseaseAmerican Journal of Gastroenterology, 2016
- Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical RecordDigestive Diseases and Sciences, 2015
- Promises and Pitfalls in the Use of “Big Data” for Clinical ResearchJournal of Dental Research, 2015
- Intelligent use and clinical benefits of electronic health records in rheumatoid arthritisExpert Review of Clinical Immunology, 2015
- Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers.2015
- Performance of the Aspartate Aminotransferase-to-Platelet Ratio Index for the Staging of Hepatitis C-Related Fibrosis: An Updated Meta-Analysis §ΔHepatology, 2010
- The NAFLD fibrosis scoreHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006